De-risking drug discovery with ADDME - Avoiding Drug Development Mistakes Early

Katya Tsaioun, Mary Jacewicz

Research output: Contribution to journalArticlepeer-review

Abstract

The advent of early Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) screening has increased the elimination rate of weak drug candidates early in the drug-discovery process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons. This paper reviews the history of ADMET screening and why it has become so important in drug discovery and development. Assays that have been developed in response to specific needs, and improvements in technology that result in higher throughput and greater accuracy of prediction of human mechanisms of toxicity, are discussed. The paper concludes with the authors' forecast of new models that will better predict human efficacy and toxicity.

Original languageEnglish (US)
Pages (from-to)47-55
Number of pages9
JournalATLA Alternatives to Laboratory Animals
Volume37
Issue numberSUPPL. 1
DOIs
StatePublished - Sep 2009
Externally publishedYes

Keywords

  • ADME
  • ADMET
  • DMPK
  • Drug discovery
  • Drugability
  • PK
  • Pharmacokinetic studies
  • Toxicity
  • Toxicology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Toxicology
  • Medical Laboratory Technology

Fingerprint

Dive into the research topics of 'De-risking drug discovery with ADDME - Avoiding Drug Development Mistakes Early'. Together they form a unique fingerprint.

Cite this